BioAI Announces Strategic Partnership with Arbele Bio to advance Predictive AI-Models in Oncology Clinical Trials
recent articles
Nijmegen, The Netherlands – LUMO Labs’ pre-seed investment vehicle LUMO Fund II TTT AI announces an investment in Aiosyn B.V. Aiosyn’s clinical diagnostics platform uses AI-powered pathology algorithms to support pathologists with more...
Multi-year agreement will power 100% digitization of Uppsala’s clinical workflow and future AI integrations UPPSALA, Sweden & PHILADELPHIA, PA - February 3, 2022 - Proscia®, the leader in digital and computational...
In honor of World Cancer Day, The Desmoid Tumor Research Foundation is celebrating the success of their virtualized tumor board program enabled through the OncoLens platform Atlanta, GA: In honor of World Cancer Day on February 4th, The...
Motic Presents: Adopting Digital Pathology: The Guide To Implementation Summary: In this guide, you will learn Easy steps to start adopting digital pathology Why reliability and product support affects your reputation ...
February 2, 2022 -- Artemis DNA’s two facilities, in Irvine, California and Houston, Texas, are now both CLIA and CAP accredited. Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high...
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet...
